ReviewAmerican journal of physiology. Heart and circulatory physiology2026
The pathophysiology of wild-type transthyretin amyloidosis: implications for exercise intolerance.
Review in American journal of physiology. Heart and circulatory physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Wild-type transthyretin amyloidosis (ATTRwt) is an age-associated protein misfolding disorder marked by extracellular deposition of transthyretin fibrils within the myocardium, peripheral nerves, lungs, blood vessels, and musculoskeletal tissues. ATTRwt typically presents as a restrictive cardiomyopathy with preserved left ventricular ejection fraction that contributes to the development of hallmark symptoms such as exercise intolerance. Amyloid infiltration severely impairs ventricular compliance and diastolic reserve, limiting stroke volume and cardiac output augmentation during exercise, and is frequently accompanied by coronary microvascular dysfunction. These central limitations are compounded by autonomic dysfunction, including chronotropic incompetence and impaired sympathetic vasomotor control, which blunt heart rate responses and disrupt appropriate blood flow responses. Pulmonary hypertension, right ventricular-pulmonary artery uncoupling, and ventilatory inefficiency further constrain oxygen transport and contribute to exertional dyspnea and early fatigue. Other peripheral factors such as amyloid-related derangements in vascular endothelial function and musculoskeletal pathologies likely result in impaired hyperemic responses to exercise and accelerated cardiovascular deconditioning, further limiting physical capacity. Together, these integrated cardiac, pulmonary, autonomic, and peripheral abnormalities convergently impair exercise performance in ATTRwt. Considering the universal presentation of exercise intolerance in ATTRwt, therapies that may have favorable effects on physical capacity are of great interest to patients, physicians, and scientists alike. This review seeks to synthesize current evidence describing the central and peripheral pathophysiological mechanisms underlying exercise intolerance in ATTRwt and discuss the potential of pharmacologic and exercise-based interventions that may improve physical capacity in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.